

**AUDITED STANDALONE FINANCIAL RESULTS
 FOR THE YEAR ENDED 31st MARCH, 2011**

(Rupees in crores)

Particulars	Year Ended	
	31.03.2011	31.03.2010
1. a) Gross Sales	6183.87	5411.68
Less: Excise Duty	48.71	52.16
Net Sales	6135.16	5359.52
b) Other Operating Income	194.14	265.39
Total Operating Income (a+b)	6329.30	5624.91
2. Expenditure		
a) (Increase)/decrease in Stock-in-trade and work in progress	(125.74)	(265.19)
b) Consumption of Materials	2343.15	2114.11
c) Purchase of Traded Goods	671.13	621.66
d) Employee Cost	540.33	371.08
e) Depreciation	248.03	187.84
f) Other Expenditure	1600.45	1430.09
g) Total	5277.35	4459.59
3. Profit (+)/Loss (-) from Operations before Other Income, Interest & Exceptional Items (1-2)	1051.95	1165.32
4. Other Income	104.58	88.33
5. Profit (+)/Loss (-) before Interest & Exceptional Items (3+4)	1156.53	1253.65
6. Interest	5.14	23.66
7. Profit (+)/Loss (-) after Interest but before Exceptional Items (5-6)	1151.39	1229.99
8. Exceptional items	-	95.00
9. Profit (+)/Loss (-) before Tax (7+8)	1151.39	1324.99
10. Tax Expense*	191.00	243.50
11. Net Profit (+)/Loss (-) after Tax (9-10)	960.39	1081.49
12. Paid-up Equity Share Capital (Face Value Rs.2 per share)	160.58	160.58
13. Reserves excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year	6443.39	5744.54
14. Earning per Share (Rs.)	11.96	13.69
15. Public Shareholding		
- Number of Shares	503606049	500849336
- Percentage of Shareholding	62.72	62.38
16. Promoters and Promoter Group Shareholding		
a) Pledged/Encumbered		
- Number of Shares	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL
- Percentage of shares (as a % of the total share capital of the Company)	NIL	NIL
b) Non Encumbered		
- Number of Shares	295485978	295485978
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00
- Percentage of shares (as a % of the total share capital of the Company)	36.80	36.80

Notes:

1. The Company is essentially in the pharmaceutical business segment.
2. The Directors at their meeting held today recommended payment of final dividend of Rs.2 per equity share (face value Rs.2) for the year 2010-2011 amounting to Rs.160.58 crores. In September 2010, the Company paid an interim dividend of 80 paise per equity share (face value Rs.2) for the year 2010-2011.
3. In 2003, the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High Courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by separate orders restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1230.28 crores (inclusive of interest) for the period July 1995 to April 2009.
4. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
5. The Audited Standalone Statement of assets and liabilities is as under:

Particulars	(Rs. in Crores)	
	Year ended	
	31.03.2011	31.03.2010
Shareholders Funds		
(a) Capital	160.58	160.58
(b) Reserves and Surplus	6638.99	5753.51
Loan Funds	441.39	5.07
Deferred Tax Liabilities	212.45	179.15
Total	7453.41	6098.31
Fixed Assets	3121.08	2695.41
Investments	570.28	265.10
Current Assets, Loans and Advances		
(a) Inventories	1883.16	1512.58
(b) Sundry Debtors	1497.04	1552.71
(c) Cash and Bank balances	84.13	60.84
(d) Other current assets	0.36	4.70
(e) Loans and Advances	1268.88	1221.59
Less: Current Liabilities and Provisions		
(a) Liabilities	938.27	998.25
(b) Provisions	33.25	216.37
Total	7453.41	6098.31

6. *Tax expense is inclusive of current tax, deferred tax and Minimum Alternate Tax (MAT) credit.
7. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 29th June, 2011.

By order of the Board
For CIPLA LIMITED



M. K. Hamied
Joint Managing Director

Mumbai
29th June, 2011